openPR Logo
Press release

SGS Helps Manufacturers Understand Brazilian Regulations for Medical Devices

05-09-2019 07:17 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: SGS

/ PR Agency: Sugarloaf Marketing
Brazil is currently one of the fastest growing markets for medical devices in the world. To access it, manufacturers and suppliers must test their products for quality, safety and efficacy, to ensure they meet mandatory requirements set out by the National Health Surveillance Agency – ANVISA. Certification that the product conforms to these requirements must be carried out by a certification body accredited by CGCRE – General Coordination for Accreditation of INMETRO.

Medical devices are defined by ANVISA as equipment, including parts and accessories, for medical, laboratorial or physiotherapeutic purposes. They can be used either directly or indirectly for diagnosis, treatment, rehabilitation or monitoring, and it includes equipment for beauty and aesthetic purposes. This definition comes from Resolution RDC Nr 27, issued June 21, 2011.

Stakeholders should also consider ANVISA’s Normative Instructions Nr 04, Nr 22 and Nr 29, which bring together all applicable standards that must be considered when determining whether a product is eligible for certification. They also include the deadline from which certification becomes mandatory.

Products that require certification include:
• Diagnostic equipment
• Therapy equipment
• Medical-hospital support equipment
• Disposable materials and devices
• Medical-hospital support materials and devices
• Beauty and aesthetics devices
• Motorized and manual wheelchairs

Stakeholders should be aware, ANVISA makes the final decision on CGCRE certification. To gain ANVISA approval, manufacturers can either go through cadaster (simpler and faster for lower-risk devices) or registration. Approval is by a Good Manufacturing Practice (GMP) audit for either approval route, which both require similar documentation.

The audit is performed directly by ANVISA and it must be completed before registration submission, as certification is a pre-requisite for some products. Products must be classified before registration to determine if a GMP audit will be required.

Medical devices covered by any standard included in Normative Instructions Nr 04, Nr 22 and Nr 29, considering their respective deadlines, must be certified by an Organization of Certification of Product (OCP) and display the INMETRO mark. This certification confirms the quality of a system, process, product or service, and is achieved through the evaluation and review of compliance with specified requirements, technical standards and technical regulations. All processes are defined in ORD54 (INMETRO, February 1, 2016). Certificates issued in accordance with the previous instruction, ORD350, remain valid until their expiration date unless there is a significant change, in which case they must be certified to ORD54.

The evaluation process used by Product Certification Bodies (PCB) can be summarized as:

1. Initial assessment: formal request to the PCB of the product with the minimum documentation
2. Initial factory inspection: focus ISO 13485 clauses and routine tests, according to clauses 8.6, 8.7 and 8.8 of IEC 60601-1. Conducted on 100% of products bearing INMETRO mark. There is additional request to validate the requirements of IEC 60601-1-6, IEC 60601-1-9, IEC 62304 and ISO 14971 during audits
3. Test reports: issued only by laboratories accredited by members of ILAC, IAAC or EA according to all applicable IEC standards. Reports must be issued no more than 2 years ago, or 4 years ago for big size products, considering the date of initial certification process and must be redone upon renewal
4. Factory inspections: must be performed every 15 months to maintain certification – four audits in five-year certification period of validity
5. Imported products: Brazilian local representative inspected to check compliance with the requirements of ORD54 (customer complaints, traceability control of the products bearing the compliance seal, product preservation, etc.). Performed every 15 months

ORD54 requires harmonization with the third iteration of the IEC 60601 standards, which will affect document analysis and factory inspections. In the past, no Brazilian laboratory could conduct tests according to this series of standards and so test reports to the second edition were accepted. Transition to edition three has, however, the full backing of all stakeholders, and currently Brazilian laboratories can carry out tests according to most of the standards in this series.

Finally, manufacturers and suppliers need to also consider:
• Import controls – customs agents check medical devices at the border against ANVISA databases to ensure compliance
• Monitoring certification – periodic audits performed on factories and suppliers to ensure continued compliance of product and processes, for medical electrical equipment certification. NB. design changes instigated during the five-year period of validity must be reported and approved in advance
• Local representation – to sell in Brazil, manufacturers must have a local representative within the country who acts on behalf of the supplier in all product-related matters

SGS Medical Device Services
SGS has over 70 years’ experience of working in Brazilian markets. Their expertise in compliance management lets them deliver fully CGCRE-accredited, independent and innovative services to the medical device sector using state-of-the-art facilities. They provide tailor-made services with rapid turnaround times, value-based pricing, technical assistance and key account management. Learn more about SGS Medical Device Services: [www.sgs.com/medicaldevices]

For more information, contact:

Andréa de Souza
MED - Team leader
Email: crs.media@sgs.com
Website: www.sgs.com/medicaldevices

SGS is the world’s leading inspection, verification, testing and certification company. SGS is recognized as the global benchmark for quality and integrity. With more than 97,000 employees, SGS operates a network of over 2,600 offices and laboratories around the world.

1, Mons Calpe
Chitcombe Road
Broad Oak
Rye
East Sussex
TN31 6EU

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release SGS Helps Manufacturers Understand Brazilian Regulations for Medical Devices here

News-ID: 1732763 • Views: 521

More Releases from SGS

Experienced Willy Fabritius Joins SGS
With over a quarter of a century of experience in IT, information security and international standards, Willy Fabritius has joined world-leading testing, inspection and certification company SGS. Willy accepted the role of Global Head of Strategy and Business Development, Information Security Assurance this summer. He says: “I am delighted to join SGS, which has the incredible reputation of providing superb information security solutions across the world. “I will use my in-depth knowledge
SGS opens doors to new markets with publication of latest ‘Global Access Progr …
SGS, the world’s leading inspection, verification, testing and certification company, is pleased to announce publication of the latest version of its Global Access Program (GAP) for Electrical & Electronics Products white paper. With the continuous growth of worldwide trading business, and more countries and regions establishing their own type-approval systems, the GAP white paper has become an essential reference for Electrical & Electronics (E&E) manufacturers and importers looking to reach new
Ecuador Issues Revised Draft Technical Regulation on Food Contact Ceramics
Ecuador has announced a revised proposal that, if accepted, will update its technical regulation for food contact ceramics. The latest proposal, designated Ecuadorian Technical Regulation RTE UNEN 010 (2R) – ‘Ceramic Tableware Intended to Come into Contact with Food’, was circulated attached to World Trade Organization (WTO) document no. 20-4675 on July 8, 2020. It has a new structure and contains several important changes, including: • Revision to existing definitions and
SGS puts Consumer Trust at the Heart of its new Brand Awareness Campaign
SGS, the world’s leading inspection, testing and certification company, has today launched ‘Trusted. Tested.’ – a high impact, brand awareness campaign to engage consumers in the vital role of testing, inspection and certification on the everyday products they purchase. With the strapline ‘It’s only trusted because it’s tested’, the campaign showcases more than 50 everyday products that typically pass through SGS’s testing laboratories – from lipsticks and shoes to mobile phones

All 5 Releases


More Releases for ANVISA

Europe Immunochemistry Market is expected to reach US$ 775.97 Mn in 2027: Agenci …
The Europe immunochemistry market is expected to reach US$ 775.97 Mn in 2027 from US$ 430.82 Mn in 2018. The market is estimated to grow with a CAGR of 6.9% from 2019-2027. The growth of the immunochemistry market is primarily attributed to the significantly increasing prevalence of cardiovascular diseases and rising incidence of diabetes in the region. However, shortage of skilled professionals is likely to have a negative impact on market
Cannabis Testing Market Analysis 2018-2025: Digipath Labs, Agilent Technologies, …
Global cannabis testing market is expected to grow in the coming years, owing to the factors such as, legalization of medical cannabis, increasing awareness through conferences, symposia, and workshops and growing adoption of LIMS in cannabis testing laboratories. However, the stringent regulatory framework for cannabis and dearth of trained laboratory professionals act as a restraint for this market. On the other hand, advances in cannabis testing equipments likely to add
Aesthetic Thread Market is expected to register a CAGR of 5.7% during the foreca …
Market Analysis: Asia-Pacific Expected to Record High CAGR The Asia-Pacific aesthetic thread market is expected to register high CAGR when compared to other regional markets, due to the booming cosmetic industry, which has become one of the most exciting fields for business in the region, especially China, in the recent years. Detailed Sample Copy of Updated Analysis @ https://marketprognosis.com/sample-request/17167 Note: “If this link doesn’t work in Internet Explorer, kindly try pasting it in
Active Pharmaceutical Ingredient Market Worth US$ 186 Bn Globally by 2020 End
According to a new market report published by Persistence Market Research “Active Pharmaceutical Ingredient (API) Market” the global active pharmaceutical ingredient market was valued at US$ 127 Bn in 2014 and is estimated to reach US$ 186 Bn by 2020 at a CAGR of 6.6% from 2015 to 2020. Active pharmaceutical ingredient (API) refers to a therapeutically active ingredient or substance combination used in manufacturing a drug product. Production of active
Global Active Pharmaceutical Ingredients (API) Market is Anticipated to Grow US$ …
According to a new market report published by Persistence Market Research “Active Pharmaceutical Ingredient (API) Market” the global active pharmaceutical ingredient market was valued at US$ 127 Bn in 2014 and is estimated to reach US$ 186 Bn by 2020 at a CAGR of 6.6% from 2015 to 2020. Active pharmaceutical ingredient (API) refers to a therapeutically active ingredient or substance combination used in manufacturing a drug product. Production of active
Global Glycobiology Market will Reach US$ 1,670.3 Million by 2024
According to a new market report published by Persistence Market Research “Active Pharmaceutical Ingredient (API) Market” the global active pharmaceutical ingredient market was valued at US$ 127 Bn in 2014 and is estimated to reach US$ 186 Bn by 2020 at a CAGR of 6.6% from 2015 to 2020. Active pharmaceutical ingredient (API) refers to a therapeutically active ingredient or substance combination used in manufacturing a drug product. Production of active